chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 47-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 13Mar2024 as dose 1, single (Batch/Lot number: unknown) at the age of 45 years for covid-19 immunisation. The patient's relevant medical history included: "CFS" (unspecified if ongoing); "Penicillin allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE), for COVID-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunization; Covid-19 vaccine (DOSE 4 (BOOSTER), SINGLE), for COVID-19 Immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2024, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 and included treatment with Paxlovid from 06May2024.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 67-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 31Oct2022 as dose 6 (booster), single (Lot number: GL0446) for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single), as dose 3 (booster), single), as dose 4 (booster), single) and as dose 5 (booster), single) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included PAXLOVID taken from  13May2024 to 17May2024.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 60-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 14Sep2023 as dose 1, single (Batch/Lot number: unknown) at the age of 59 years for covid-19 immunisation. The patient's relevant medical history included: "hypothroid" (unspecified if ongoing); "psoriatic arthritis" (unspecified if ongoing). Concomitant medication(s) included: METHOTREXATE; SYNTHROID; EVISTA; TYLENOL. The patient also took other concomitant therapy. Vaccination history included: Covid-19 vaccine (Primary immunization series completed., Manufacturer unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 3), for Covid-19 Immunization; Covid-19 vaccine (Dose: 4), for Covid-19 Immunization; Covid-19 vaccine (Dose: 5), for Covid-19 Immunization; Covid-19 vaccine (Dose: 6), for Covid-19 Immunization; Covid-19 vaccine (Dose: 7), for Covid-19 Immunization. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of covid-19, drug ineffective.
Age: 0.17
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: No adverse event, Product preparation error
Clinical narrative: Pentacel vaccine not reconstituted- DTaP and IPV components administered, Hib component not given. No acute s/s of adverse reaction noted by clinic nurse or reported.
Age: 5.0
Sex: M
Vaccine: UNK, UNK, UNK
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Accidental administration of IVP Polio .  Was not needed because DTaP (Quadracel) already has Polio in it.   Checked on the child via mother on morning of 05/21/2024 (same day attempt to contact was unsuccessful).  Mother reports no adverse effects.  No fever, irritability, or other symptoms to report.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Right arm red, swollen. painful. Hot to the touch.
Age: 74.0
Sex: F
Vaccine: UNK
Symptoms: Nasal mucosal blistering, Oral herpes
Clinical narrative: Severe fever blisters in nose and on lips
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Arrhythmia, Chronic fatigue syndrome, Palpitations
Clinical narrative: Arrhythmias, heart palpitations,  Myalgicencophalomyelitis
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chronic lymphocytic leukaemia, Full blood count
Clinical narrative: CLL
Age: 43.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Nephrectomy, Renal mass
Clinical narrative: Patient with mass in left kidney, Left nephrectomy done
Age: 65.0
Sex: F
Vaccine: PNC20
Symptoms: Exercise tolerance decreased, Incorrect route of product administration, Injection site pain, Joint injection, Joint range of motion decreased
Clinical narrative: Vaccine was given very high into shoulder joint and was extremely painful on administration. Pain increased over the course of several days and became severe, limiting active range of motion and ability to perform tasks with the left arm.  Painful at night, interfering with sleep.   Severe pain  9/10 for 3-4 weeks.  Improved slightly and plateaued at 4-6 weeks.  Discussed with colleague from Sports Medicine who recommended exercises and stretches for rotator cuff injury.  I was unable to tolerate the exercises and on 3/21/2024, I went to Ortho Walk-in.  Xrays done. Joint injection performed, which after initial increase in pain, did relieve the pain for approximately 3-4 weeks. Pain then returned.  Visit with Dr. at Orthopedics for follow-up. Concern for SIRVA. MRI recommended  before PT and scheduled 5/31/2024
Age: 65.0
Sex: F
Vaccine: PNC20
Symptoms: Loss of personal independence in daily activities, Pain, Product administered at inappropriate site, Rotator cuff syndrome, Sleep disorder
Clinical narrative: Vaccine was given very high into shoulder joint and was extremely painful on administration. Pain increased over the course of several days and became severe, limiting active range of motion and ability to perform tasks with the left arm.  Painful at night, interfering with sleep.   Severe pain  9/10 for 3-4 weeks.  Improved slightly and plateaued at 4-6 weeks.  Discussed with colleague from Sports Medicine who recommended exercises and stretches for rotator cuff injury.  I was unable to tolerate the exercises and on 3/21/2024, I went to Ortho Walk-in.  Xrays done. Joint injection performed, which after initial increase in pain, did relieve the pain for approximately 3-4 weeks. Pain then returned.  Visit with Dr. at Orthopedics for follow-up. Concern for SIRVA. MRI recommended  before PT and scheduled 5/31/2024
Age: 65.0
Sex: F
Vaccine: PNC20
Symptoms: X-ray limb normal
Clinical narrative: Vaccine was given very high into shoulder joint and was extremely painful on administration. Pain increased over the course of several days and became severe, limiting active range of motion and ability to perform tasks with the left arm.  Painful at night, interfering with sleep.   Severe pain  9/10 for 3-4 weeks.  Improved slightly and plateaued at 4-6 weeks.  Discussed with colleague from Sports Medicine who recommended exercises and stretches for rotator cuff injury.  I was unable to tolerate the exercises and on 3/21/2024, I went to Ortho Walk-in.  Xrays done. Joint injection performed, which after initial increase in pain, did relieve the pain for approximately 3-4 weeks. Pain then returned.  Visit with Dr. at Orthopedics for follow-up. Concern for SIRVA. MRI recommended  before PT and scheduled 5/31/2024
Age: 37.0
Sex: M
Vaccine: PPV
Symptoms: Erythema, Pain, Pruritus, Swelling
Clinical narrative: First 2 days swelling and pain. Used ice pack and tylenol. 3rd or 4th day started to get red and itch. 5th day redness had gotten bigger, went to Dr.
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Pain of skin, Rash, Rash pruritic, Rash vesicular
Clinical narrative: BLISTERY LESION  ON HANDS, ARMS, LEGS, AND FEET. LASTED FOR 4-6 WEEKS, VISITED THE DOCTOR AND WAS PRESCRIBED STERIODS AND PAIN MEDICATION. THEY WERE ITCHY AND PAINFUL, HARD TO  TOUCH THINGS. IT WAS STARTED IMMEDITELY AND VISITED NEXT DAY.
Age: 77.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Cough, SARS-CoV-2 test
Clinical narrative: Cough
Sex: U
Vaccine: HEPA
Symptoms: Product storage error
Clinical narrative: Medical assistant reported VAQTA was administered after a temperature excursion to patient. Date of administration: 4/16/2024.  Names of vaccines involved (including lot/exp): VAQTA (X025482 4/12/2025) Temperature: 32.9°F Time frame: 3 hours 18 minu; No additional AE reported.; This spontaneous report has been received from a medical assistant, regarding a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug allergies or concomitant medications were not reported.  On 16-APR-2024, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, once, lot number X025482, expiration date: 12-APR-2025, administered for prophylaxis by a healthcare professional (dose, vaccination scheme, route of administration, and anatomical site of injection were not provided), after a temperature excursion (product storage error). The temperature of the vaccine administered was reported as 32.9 degrees Fahrenheit, at a timeframe of 3 hours and 18 minutes with no previous temperature excursions.  No further information was provided. No additional adverse events reported. ; Sender's Comments:  US-009507513-2405USA000970: US-009507513-2405USA001088: US-009507513-2405USA001251:2405USA001031 US-009507513-2405USA001261:2405USA001031 US-009507513-2405USA000954:
Sex: U
Vaccine: HEPA
Symptoms: No adverse event, Product storage error
Clinical narrative: Medical assistant reported VAQTA was administered after a temperature excursion to patient. Date of administration: 4/11/2024.  Names of vaccines involved (including lot/exp): VAQTA (X025482 4/12/2025) Temperature: 32.9°F Time frame: 3 hours 18 minu; No additional AE reported.; This spontaneous report has been received from a medical assistant, regarding a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug allergies or concomitant medications were not reported.  On 11-APR-2024, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, once, lot number X025482, expiration date: 12-APR-2025, administered for prophylaxis (dose, vaccination scheme, route of administration, and anatomical site of injection were not provided), after a temperature excursion (product storage error). The temperature of the vaccine administered was reported as 32.9 degrees Fahrenheit, at a timeframe of 3 hours and 18 minutes with no previous temperature excursions.  No further information was provided. No additional adverse events reported. ; Sender's Comments:  US-009507513-2405USA000970: US-009507513-2405USA001088: US-009507513-2405USA001251:2405USA001055 US-009507513-2405USA001261:2405USA001055 US-009507513-2405USA000954:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: Medical assistant reported ROTATEQ was administered after a temperature excursion to patient. Date of administration: 5/1/2024 Names of vaccines involved (including lot/exp): ROTATEQ (1968386 5/23/2024) Temperature: 32.9°F Time frame: 3 hours 18 min; No additional AE reported.; This spontaneous report has been received from a medical assistant, regarding a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug allergies or concomitant medications were not reported.  On 01-MAY-2024, the patient was vaccinated with virus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, frequency of 1 dose, lot #1968386, expiration date: 23-MAY-2024, administered orally for prophylaxis (dose and vaccination scheme were not provided), after a temperature excursion (product storage error). The temperature of the vaccine administered was reported as 32.9 degrees Fahrenheit, at a timeframe of 3 hours and 18 minutes with no previous temperature excursions.  No further information was provided. No additional adverse events reported.; Sender's Comments:  US-009507513-2405USA000970: US-009507513-2405USA001088: US-009507513-2405USA001251:2405USA001064 US-009507513-2405USA001261:2405USA001064 US-009507513-2405USA000954:
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Vaginal haemorrhage
Clinical narrative: vaginal bleed; This spontaneous case was reported by a patient and describes the occurrence of VAGINAL HAEMORRHAGE (vaginal bleed) in a 77-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    On 16-May-2024, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On 18-May-2024,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced VAGINAL HAEMORRHAGE (vaginal bleed). At the time of the report, VAGINAL HAEMORRHAGE (vaginal bleed) outcome was unknown.            No concomitant medications were reported. Treatment medications were not provided.
Age: 1.25
Sex: M
Vaccine: DTPPVHBHPB, HIBV
Symptoms: Extra dose administered, No adverse event
Clinical narrative: patient was given the acthib and vaxelis at the same time with no reported adverse event; Initial information was received on 14-May-2024 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 15 months old male patient to whom  HIB (PRP/T) VACCINE [ACT-HIB] and VAXELIS was given at the same time with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 14-May-2024, the patient received 0.5 ml, total dose of suspect HIB (PRP/T) vaccine, Powder and solvent for solution for injection (lot UJ978AA, expiry date, strength: standard) via intramuscular route and patient received an unknown dose of suspect VAXELIS not produced by Sanofi Pasteur (unknown formulation) (lot U7788AA, expiry date, strength, was unknown) via unknown route in unknown administration site for Immunization and was given the acthib and vaxelis at the same time with no reported adverse event (extra dose administered) (Latency: same day).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.25
Sex: U
Vaccine: HIBV
Symptoms: Expired product administered
Clinical narrative: An expired ACT-HIB was administered to a 3 month old with no adverse event; Initial information received on 17-May-2024 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp (health care professional).  This case involves a 3 months old and unknown gender patient who was administered expired HIB (PRP/T) Vaccine [ACT-HIB] with no adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 17-May-2024, the patient had received expired (dose and units unspecified) suspect HIB (PRP/T) Vaccine (Powder and solvent for solution for injection) (lot UJ835AA; expiry date: 22-Feb-2024; strength: standard) via unknown route in unknown administration site for Immunization (expired product administered) (latency-same day).   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 49.0
Sex: F
Vaccine: TD, TDAP
Symptoms: No adverse event, Wrong product administered
Clinical narrative: patient received TENIVAC instead of ADACEL with no reported adverse event; Initial information received on 17-May-2024 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 49 years old female patient who received diphtheria-2/tetanus-5 adsorbed toxoids no preservative adult [Tenivac] instead of diphtheria-2/tetanus/5 AC pertussis vaccine [Adacel] with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 17-May-2024, the patient received a dose 0.5 ml (frequency: once; strength: standard) of suspect Diphtheria-2/Tetanus-5 Adsorbed Toxoids No Preservative Adult Suspension for injection (expiry date, lot number: not reported) via intramuscular route in the left deltoid for immunization instead of Diphtheria-2/Tetanus/5 AC Pertussis Vaccine (Adacel) (wrong product administered) (latency: on same day). Information on batch number was requested.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: I started to have tinnitus sometimes last year, it was significant, and I don't remember the exact start date/month. But recently, the tinnitus has gotten worse and sometimes it become unbearable.  I searched online and was instructed to report to VAERS. I never see doctor for the symptom.
Age: 4.0
Sex: F
Vaccine: VARCEL
Symptoms: Herpes zoster, Pain, Pain of skin, Rash
Clinical narrative: At 21 years old, I have just been diagnosed with Shingles. I never had chickenpox and received two doses of Varivax on 02/18/2004 and 10/24/2006. Symptoms started 05/13/2024 which included pain on the left side of my ribcage. My skin was painful to touch and sensitive to temperature. The pain started in one spot on the side of my ribcage, underneath the armpit, and spread slightly to my back and underneath and on my left breast. I was diagnosed with shingles 05/15/2024 and was given valacyclovir. I developed a slight rash 05/18/2024 but it was not more than a few bumps and they went away two days later. The pain still remained and remains to this day.
Age: 53.0
Sex: F
Vaccine: COVID19-2
Symptoms: Abdominal pain upper, Blood test normal, Chest X-ray normal, Chest discomfort, Chest pain
Clinical narrative: Went to emergency room due to alarming chest  pain 1 week after vaccine. Advised to take Ibuprofen. 1.5 weeks after vaccine upper stomach pain started (pain lying down) accompanied continued chest pain and tightness in the chest. Chest pain eased a bit for a week or so, when the stomach pain started, but is back again one month later (5/23) and is starting to interfere with my ability to sleep. Since the pain started I have only been able to sleep on my back due to the discomfort of any other position.
Age: 53.0
Sex: F
Vaccine: COVID19-2
Symptoms: Discomfort, Sleep disorder, Troponin normal
Clinical narrative: Went to emergency room due to alarming chest  pain 1 week after vaccine. Advised to take Ibuprofen. 1.5 weeks after vaccine upper stomach pain started (pain lying down) accompanied continued chest pain and tightness in the chest. Chest pain eased a bit for a week or so, when the stomach pain started, but is back again one month later (5/23) and is starting to interfere with my ability to sleep. Since the pain started I have only been able to sleep on my back due to the discomfort of any other position.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Eating disorder, Immediate post-injection reaction, Loose tooth, Speech disorder, Tooth fracture
Clinical narrative: teeth pain cracking, falling out Loose. This is the 3rd time I am begging for your help. My daughter and I took the 1st & 2nd dose of the Covid vaccine. Almost immediately after the 1st dose we experienced tooth ache and breakage. The second vaccine it was evident our teeth were breaking and falling out. Today we can barely eat or speak clearly. My daughter is experiencing ear ache and bloody nose, headaches. Please refer us to a dentist-oral surgeon. We did what we were told to do and it went wrong for us. Please help.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tooth loss, Toothache
Clinical narrative: teeth pain cracking, falling out Loose. This is the 3rd time I am begging for your help. My daughter and I took the 1st & 2nd dose of the Covid vaccine. Almost immediately after the 1st dose we experienced tooth ache and breakage. The second vaccine it was evident our teeth were breaking and falling out. Today we can barely eat or speak clearly. My daughter is experiencing ear ache and bloody nose, headaches. Please refer us to a dentist-oral surgeon. We did what we were told to do and it went wrong for us. Please help.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear pain, Epistaxis, Headache, Loose tooth, Tooth fracture
Clinical narrative: Soon after 2X Covid shots experienced toothaches, headaches, tooth cracking breaking Loosing, earaches, nose bleeds, Loose teeth
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Toothache
Clinical narrative: Soon after 2X Covid shots experienced toothaches, headaches, tooth cracking breaking Loosing, earaches, nose bleeds, Loose teeth
Age: 0.83
Sex: F
Vaccine: PNC15
Symptoms: Injection site urticaria, Urticaria
Clinical narrative: pt developed hives at injection site that then spread to other parts of the body within 24 hrs of injection.  Mom was instructed to give appropriate dosage of Benadryl for child weight.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Cough, Fatigue, Headache, SARS-CoV-2 test
Clinical narrative: Fatigue, minimal cough, headache, chills
Age: 64.0
Sex: M
Vaccine: FLU4
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No adverse events or outcomes.  Patient was 64 years and 11 months old with chronic health issues and provider wanted patient to have high dose flu vaccine.
Age: 32.0
Sex: F
Vaccine: HPV9
Symptoms: Blood pressure increased, Chest discomfort, Chest pain
Clinical narrative: Patient stated experiencing chest pain/tightness, elevated blood pressure after receiving vaccine. Patient has doctors appointment scheduled for today for follow up.
Age: 56.0
Sex: M
Vaccine: SMALLMNK
Symptoms: Incorrect route of product administration
Clinical narrative: Jynneos was administered 0.5ml intramuscularly instead of subcutaneously. Dose is expected to be effective and no readministration necessary. Patient denied any rash or discomfort other than expected sore arm after dose.
Age: 24.0
Sex: F
Vaccine: HEPA, HPV9, TDAP
Symptoms: Injection site induration, Injection site swelling, Injection site warmth, Pain, Peripheral swelling
Clinical narrative: Patient reports that about 2 hours after having vaccines that her right arm (TDAP) started to swell.  Today she presents to clinic with a swollen right deltoid with hardness and warm to the area that measures 70mm x 70 mm.  She reports no pain to touch but has pain with certain movements.  She has not tried any relief measures (OTC pain medication, ice, etc.).    Patient had received TDaP (Boostrix/GlaxoSmith/Kline) on 02/03/2011 with no adverse reaction.   Private vaccine purchased by county.
Age: 20.0
Sex: M
Vaccine: FLU4, TDAP
Symptoms: Immediate post-injection reaction, Syncope
Clinical narrative: Patient fainted. Suspected vasovagal  syncope.  No significant injury. Developed right after injection <1 min.
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: Arthralgia, Hypersensitivity, Nasal congestion
Clinical narrative: Shoulder area pain, chronic issues with congestion and allergies. Starting the day after vaccination. Takes cetirizine and phenylephrine to help alleviate the symptoms and they return by end of day.
Age: 22.0
Sex: F
Vaccine: HPV9
Symptoms: Arthralgia, Pain, Pain in extremity, Pyrexia, Sleep disorder
Clinical narrative: Severe arm and shoulder pain that radiated down to elbow; started the morning after vaccine administered; Today is one week and one day since vaccine and arm is still hurting; can't move shoulder fully without pain; took IB and helped very little; felt a little feverish but did not take temperature; Interrupting sleep due to pain
Age: 3.0
Sex: M
Vaccine: DTPPVHBHPB, IPV, MMRV, PNC20
Symptoms: Extra dose administered
Clinical narrative: Extra does of IVP given
Age: 58.0
Sex: F
Vaccine: PNC20
Symptoms: Extra dose administered
Clinical narrative: Patient received additional dose of Prevnar 20. 1st does received on 02/07/2023 and 2nd dose received 05/21/2024.  When staff reviewed the immunization report she thought she saw that the patient had received PPV23  and was due for PCV20. Patient also was requesting the vaccine as she believed she had not received. Once patient received vaccine and staff member looked at immunization report again, she noticed that there were two different dates under the PCV20 line. This is when she noticed the patient had infact received the PCV 20 in 2023.MD and patient were both notified. No adverse reaction noted at time of patient in clinic.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash vesicular
Clinical narrative: No sure of the Brand name, but this system would no let me continue without picking one. Shingles vaccine- 21 days showed systems of chicken pox on waist area
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Pruritus
Clinical narrative: Lymph node enlargement followed by total body severe itching for last 5 days
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Discomfort, Pruritus, Rash
Clinical narrative: Lymph node enlargement followed by total body severe itching for last 5 days
Age: 0.25
Sex: F
Vaccine: DTPPVHBHPB, PNC15, RV5
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: Inadvertantly started the series when she was too old. No symptoms developed. Specifically no vomiting, abdominal pain, loose stools/diarrhea or other side effects MOP can recall.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Chills, Diarrhoea, Fatigue, Headache
Clinical narrative: On 4/5 had diarrhea, vomiting one episode - On 4/7 received J&J Covid vaccine On 4/8 , had a headache - took Aleve - got a rash, itching all over - EMS - went to hospital b/c she had severe stomach pain - was given Benadryl and pain resolved 4/17 - Developed fatigue, vomiting  4/18 - still had chills and fatigue
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Vomiting
Clinical narrative: On 4/5 had diarrhea, vomiting one episode - On 4/7 received J&J Covid vaccine On 4/8 , had a headache - took Aleve - got a rash, itching all over - EMS - went to hospital b/c she had severe stomach pain - was given Benadryl and pain resolved 4/17 - Developed fatigue, vomiting  4/18 - still had chills and fatigue
Age: 75.0
Sex: M
Vaccine: COVID19-2
Symptoms: Haematuria
Clinical narrative: Sudden onset of painless gross hematuria. Cleared over 36 hours.
Age: 19.0
Sex: F
Vaccine: HEP
Symptoms: Extra dose administered, Incorrect dose administered, No adverse event
Clinical narrative: No adverse events. Gave Engerix-B(adult dose) and patient is 5 months shy of turning 20. Gave an out of age range dose. Pt just needed the 4th dose per provider after having the titer drawn.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Bone pain, Dizziness, Myalgia, Nausea
Clinical narrative: Fever, bone and muscle aches. Treated with Tylenol at 03:00 am on 5/22/2024. At 7:00am upon rising experienced nausea,  dizziness and extreme weakness and I collapsed on the floor.  After five minutes I was able to get up with assistance and lied down in bed. Muscle and bone aches returned.  I took another dose of Tylenol.  I am hoping this will be it and I can still feeling better.  With the first three  Pfizer vaccines I  didn't experience any side-effects but with the last three I experienced similar side-effects except this
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Syncope
Clinical narrative: Fever, bone and muscle aches. Treated with Tylenol at 03:00 am on 5/22/2024. At 7:00am upon rising experienced nausea,  dizziness and extreme weakness and I collapsed on the floor.  After five minutes I was able to get up with assistance and lied down in bed. Muscle and bone aches returned.  I took another dose of Tylenol.  I am hoping this will be it and I can still feeling better.  With the first three  Pfizer vaccines I  didn't experience any side-effects but with the last three I experienced similar side-effects except this
Age: 57.0
Sex: M
Vaccine: VARZOS
Symptoms: Extra dose administered
Clinical narrative: PATIENT ACCIDENTLY RECIEVED 3RD SHINGRIX DOSE. WE WENT THROUGH CHANGE OF OWNERSHIP IN JANUARY 2024 AND HAD INSURANCE PROBLEMS UPON STARTUP AND THE 2ND SHOT WASNT DOCUMENTED IN SYSTEM
Age: 5.0
Sex: M
Vaccine: DTAPIPV
Symptoms: Product storage error
Clinical narrative: On January 9, 2024 the vaccines in the clinic were moved to Health Department due to a power outage. The power came back on around 9:30a.m. when I arrived to work but I was advised by my supervisor to move the vaccine still in case it took a while for the refrigerator to return to the proper temperature. Vaccines were packed with ice packs and bubble wrap and transported by CRNP. The vaccine was transported back to Health Department that afternoon. A temperature excursion was noted on the digital data logger. Once returned to clinic the data logger was found to be beside the ice packs instead of by the vaccine. The vaccine manufacturers of the affected vaccine were notified and made aware of the temperature excursion. I notified the companies that the vaccine reached a temperature of 1.8 degrees Celsius. The max temperature that the vaccine reached during transport was 12.0 degrees Celsius. Per the vaccine companies, the only vaccine that was not recommended to use was the opened vial of IPOL and the opened MDV of Fluzone. They were discarded per the vaccine companies? recommendations.  Moving forward to April 10, 2024. The vaccine was transported again to Health Department due to inclement weather that day. Vaccine was transported by my supervisor and returned on April 12, 2024. Another temperature excursion occurred when the vaccine was transported back to the clinic. The vaccine companies were again contacted for recommendations on viability of the vaccine. When contacting the vaccine companies, I was asked if any of the vaccines had undergone a previous temperature excursion. It was then when I pulled my documentation from the previous excursion that I realized I had read the temperature log incorrectly and that the vaccine had reached a temperature of negative 1.8 degrees Celsius instead of what I reported to the vaccine companies of a +1.8 Degrees Celsius. Therefore, in fact there were two 2 temp excursions one on January 9, 2024 and the other on April 12th, 2024.  A list of all patients that received vaccines between January 9-April 12th was compiled. The list was sorted through as to what patients received the affected vaccine. Patients were notified of questionable viability of vaccines and were offered and recommended to be revaccinated if desired. Notes were added into system for outside providers.  The process of packing vaccine during transport during emergencies had been reviewed by all staff to include packaging with conditioned water bottles instead of frozen ice packs. Parent contacted to schedule to have vaccines repeated. Appointment was scheduled on phone. Patient cancelled the appointment
Age: 51.0
Sex: F
Vaccine: TDAP
Symptoms: Cellulitis, Pain, Rash erythematous, Rash pruritic, Skin warm
Clinical narrative: large erythematous rash with itching, pain, warmth (suspect cellulitis)
Age: 26.0
Sex: F
Vaccine: HPV9
Symptoms: Product storage error
Clinical narrative: On January 9, 2024 the vaccines in the clinic were moved to Health Department due to a power outage. The power came back on around 9:30a.m. when I arrived to work but I was advised by my supervisor to move the vaccine still in case it took a while for the refrigerator to return to the proper temperature. Vaccines were packed with ice packs and bubble wrap and transported by CRNP. The vaccine was transported back to Health Department that afternoon. A temperature excursion was noted on the digital data logger. Once returned to clinic the data logger was found to be beside the ice packs instead of by the vaccine. The vaccine manufacturers of the affected vaccine were notified and made aware of the temperature excursion. I notified the companies that the vaccine reached a temperature of 1.8 degrees Celsius. The max temperature that the vaccine reached during transport was 12.0 degrees Celsius. Per the vaccine companies, the only vaccine that was not recommended to use was the opened vial of IPOL and the opened MDV of Fluzone. They were discarded per the vaccine companies? recommendations.  Moving forward to April 10, 2024. The vaccine was transported again to Health Department due to inclement weather that day. Vaccine was transported by my supervisor and returned on April 12, 2024. Another temperature excursion occurred when the vaccine was transported back to the clinic. The vaccine companies were again contacted for recommendations on viability of the vaccine. When contacting the vaccine companies, I was asked if any of the vaccines had undergone a previous temperature excursion. It was then when I pulled my documentation from the previous excursion that I realized I had read the temperature log incorrectly and that the vaccine had reached a temperature of negative 1.8 degrees Celsius instead of what I reported to the vaccine companies of a +1.8 Degrees Celsius. Therefore, in fact there were two 2 temp excursions one on January 9, 2024 and the other on April 12th, 2024.  A list of all patients that received vaccines between January 9-April 12th was compiled. The list was sorted through as to what patients received the affected vaccine. Patients were notified of questionable viability of vaccines and were offered and recommended to be revaccinated if desired. Notes were added into system for outside providers.  The process of packing vaccine during transport during emergencies had been reviewed by all staff to include packaging with conditioned water bottles instead of frozen ice packs. Patient was contacted by phone and recommended patient to have dose repeated. Patient declined to have dose repeated at this time. Patient was counseled.
Age: 52.0
Sex: M
Vaccine: TDAP
Symptoms: Product storage error
Clinical narrative: On January 9, 2024 the vaccines in the clinic were moved to Health Department due to a power outage. The power came back on around 9:30a.m. when I arrived to work but I was advised by my supervisor to move the vaccine still in case it took a while for the refrigerator to return to the proper temperature. Vaccines were packed with ice packs and bubble wrap and transported by CRNP. The vaccine was transported back to Health Department that afternoon. A temperature excursion was noted on the digital data logger. Once returned to clinic the data logger was found to be beside the ice packs instead of by the vaccine. The vaccine manufacturers of the affected vaccine were notified and made aware of the temperature excursion. I notified the companies that the vaccine reached a temperature of 1.8 degrees Celsius. The max temperature that the vaccine reached during transport was 12.0 degrees Celsius. Per the vaccine companies, the only vaccine that was not recommended to use was the opened vial of IPOL and the opened MDV of Fluzone. They were discarded per the vaccine companies? recommendations.  Moving forward to April 10, 2024. The vaccine was transported again to Health Department due to inclement weather that day. Vaccine was transported by my supervisor and returned on April 12, 2024. Another temperature excursion occurred when the vaccine was transported back to the clinic. The vaccine companies were again contacted for recommendations on viability of the vaccine. When contacting the vaccine companies, I was asked if any of the vaccines had undergone a previous temperature excursion. It was then when I pulled my documentation from the previous excursion that I realized I had read the temperature log incorrectly and that the vaccine had reached a temperature of negative 1.8 degrees Celsius instead of what I reported to the vaccine companies of a +1.8 Degrees Celsius. Therefore, in fact there were two 2 temp excursions one on January 9, 2024 and the other on April 12th, 2024.  A list of all patients that received vaccines between January 9-April 12th was compiled. The list was sorted through as to what patients received the affected vaccine. Patients were notified of questionable viability of vaccines and were offered and recommended to be revaccinated if desired. Notes were added into system for outside providers.  The process of packing vaccine during transport during emergencies had been reviewed by all staff to include packaging with conditioned water bottles instead of frozen ice packs. Patient was counseled. Tdap was repeated on 05/21/2024.
Age: 15.0
Sex: F
Vaccine: HPV9
Symptoms: Injection site erythema, Injection site induration
Clinical narrative: - HPV vaccine given on 05/13/2024, injection site red, hot to touch (left deltoid), and area is hard to touch. -Denies medication intake for symptoms.  At today's visit, patient was prescribed:  Cephalexin 500 mg tablet - Take 1 tab by mouth three times a day and  Medrol dose pack- use as directed. Advised patient to return if symptoms worsened,
Age: 5.0
Sex: F
Vaccine: DTAP, HEPA, IPV, MMRV
Symptoms: Extra dose administered, No adverse event
Clinical narrative: no symptoms
Age: 90.0
Sex: F
Vaccine: PNC20
Symptoms: Asthenia, Feeling hot
Clinical narrative: face felt warm, weakness, throat issues
Age: 65.0
Sex: F
Vaccine: PNC20, TDAP
Symptoms: Chills, Full blood count normal, Injection site swelling, Metabolic function test normal, Tremor
Clinical narrative: chills and shaking that lasted about  4 days, treated with tylenol; swelling in R shoulder to elbow that is still present but resolving
Age: 65.0
Sex: F
Vaccine: PNC20, TDAP
Symptoms: Urine analysis normal
Clinical narrative: chills and shaking that lasted about  4 days, treated with tylenol; swelling in R shoulder to elbow that is still present but resolving
Age: 52.0
Sex: M
Vaccine: MMRV, MMRV
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No symptoms at this time
Age: 26.0
Sex: M
Vaccine: TDAP
Symptoms: Product storage error
Clinical narrative: On January 9, 2024 the vaccines in the clinic were moved to Health Department due to a power outage. The power came back on around 9:30a.m. when I arrived to work but I was advised by my supervisor to move the vaccine still in case it took a while for the refrigerator to return to the proper temperature. Vaccines were packed with ice packs and bubble wrap and transported by, CRNP. The vaccine was transported back to Health Department that afternoon. A temperature excursion was noted on the digital data logger. Once returned to clinic the data logger was found to be beside the ice packs instead of by the vaccine. The vaccine manufacturers of the affected vaccine were notified and made aware of the temperature excursion. I notified the companies that the vaccine reached a temperature of 1.8 degrees Celsius. The max temperature that the vaccine reached during transport was 12.0 degrees Celsius. Per the vaccine companies, the only vaccine that was not recommended to use was the opened vial of IPOL and the opened MDV of Fluzone. They were discarded per the vaccine companies? recommendations.  Moving forward to April 10, 2024. The vaccine was transported again to Health Department due to inclement weather that day. Vaccine was transported by my supervisor and returned on April 12, 2024. Another temperature excursion occurred when the vaccine was transported back to the clinic. The vaccine companies were again contacted for recommendations on viability of the vaccine. When contacting the vaccine companies, I was asked if any of the vaccines had undergone a previous temperature excursion. It was then when I pulled my documentation from the previous excursion that I realized I had read the temperature log incorrectly and that the vaccine had reached a temperature of negative 1.8 degrees Celsius instead of what I reported to the vaccine companies of a +1.8 Degrees Celsius. Therefore, in fact there were two 2 temp excursions one on January 9, 2024 and the other on April 12th, 2024.  A list of all patients that received vaccines between January 9-April 12th was compiled. The list was sorted through as to what patients received the affected vaccine. Patients were notified of questionable viability of vaccines and were offered and recommended to be revaccinated if desired. Notes were added into immprint for outside providers.  The process of packing vaccine during transport during emergencies had been reviewed by all staff to include packaging with conditioned water bottles instead of frozen ice packs. Attempted to reach patient by phone and letter and no response back. Chart is flagged needs repeat Tdap.
Age: 12.0
Sex: M
Vaccine: UNK
Symptoms: Eye movement disorder, Injection site haemorrhage, Pallor, Seizure
Clinical narrative: Patient was given the vaccine, blood immediately ran down his arm, (assuming they hit a vein rather than muscle) within 2 minutes or less of that he lost all color, his eyes rolled back in his head and he started convulsing on the dr table.  This lasted about 5 minutes.
Age: 3.0
Sex: F
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Product storage error
Clinical narrative: On January 9, 2024 the vaccines in the clinic were moved to Health Department due to a power outage. The power came back on around 9:30a.m. when I arrived to work but I was advised by my supervisor to move the vaccine still in case it took a while for the refrigerator to return to the proper temperature. Vaccines were packed with ice packs and bubble wrap and transported by CRNP. The vaccine was transported back to Health Department that afternoon. A temperature excursion was noted on the digital data logger. Once returned to clinic the data logger was found to be beside the ice packs instead of by the vaccine. The vaccine manufacturers of the affected vaccine were notified and made aware of the temperature excursion. I notified the companies that the vaccine reached a temperature of 1.8 degrees Celsius. The max temperature that the vaccine reached during transport was 12.0 degrees Celsius. Per the vaccine companies, the only vaccine that was not recommended to use was the opened vial of IPOL and the opened MDV of Fluzone. They were discarded per the vaccine companies  recommendations.  Moving forward to April 10, 2024. The vaccine was transported again to Health Department due to inclement weather that day. Vaccine was transported by my supervisor and returned on April 12, 2024. Another temperature excursion occurred when the vaccine was transported back to the clinic. The vaccine companies were again contacted for recommendations on viability of the vaccine. When contacting the vaccine companies, I was asked if any of the vaccines had undergone a previous temperature excursion. It was then when I pulled my documentation from the previous excursion that I realized I had read the temperature log incorrectly and that the vaccine had reached a temperature of negative 1.8 degrees Celsius instead of what I reported to the vaccine companies of a +1.8 Degrees Celsius. Therefore, in fact there were two 2 temp excursions one on January 9, 2024 and the other on April 12th, 2024.  A list of all patients that received vaccines between January 9-April 12th was compiled. The list was sorted through as to what patients received the affected vaccine. Patients were notified of questionable viability of vaccines and were offered and recommended to be revaccinated if desired. Notes were added into system for outside providers.  The process of packing vaccine during transport during emergencies had been reviewed by all staff to include packaging with conditioned water bottles instead of frozen ice packs. DTAP given on 02/13/2024 underwent a temperature excursion; therefore, unsure of effectiveness of vaccine. Recommend dose be repeated. Attempted to contact patient by letter. Letter returned. Speaks another language so no attempt to contact by phone. Chart is flagged with DTAP needs repeated.
Age: 36.0
Sex: F
Vaccine: HEP, HEP
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: Patient was known at the time to be pregnant at 12 weeks and Heplisav-B vaccine was administered erroneously.  Estimated Due Date is around 8/28/24.  The error was discovered when the patient came for her second vaccine dose (23 weeks) and was given Engirix at that time.  (Engirix is not contraindicated during pregnancy.)  No known complications  to the pregnancy noted at this time due to the vaccination.
Age: 36.0
Sex: F
Vaccine: HEP, HEP
Symptoms: Exposure during pregnancy
Clinical narrative: Patient was known at the time to be pregnant at 12 weeks and Heplisav-B vaccine was administered erroneously.  Estimated Due Date is around 8/28/24.  The error was discovered when the patient came for her second vaccine dose (23 weeks) and was given Engirix at that time.  (Engirix is not contraindicated during pregnancy.)  No known complications  to the pregnancy noted at this time due to the vaccination.